XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease

The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.

本试验的主要研究目的为评估森妥珠单抗（xentuzumab）联合依维莫司（everolimus）与依西美坦（exemestane）的联合方案，对比单用依维莫司及依西美坦方案，在激素受体阳性（HR+）、人表皮生长因子受体2阴性（HER2-）晚期或转移性乳腺癌且伴非内脏疾病患者中的疗效。